These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25632846)

  • 21. Innate and adaptive immune responses in HCV infections.
    Heim MH; Thimme R
    J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.
    Ataie-Kachoie P; Pourgholami MH; Morris DL
    Cytokine Growth Factor Rev; 2013 Apr; 24(2):163-73. PubMed ID: 23107589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
    Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
    Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
    Mori T; Miyamoto T; Yoshida H; Asakawa M; Kawasumi M; Kobayashi T; Morioka H; Chiba K; Toyama Y; Yoshimura A
    Int Immunol; 2011 Nov; 23(11):701-12. PubMed ID: 21937456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-27 in tumor immunity and immunotherapy.
    Murugaiyan G; Saha B
    Trends Mol Med; 2013 Feb; 19(2):108-16. PubMed ID: 23306374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving knowledge and therapy of inflammatory bowel disease.
    Korzenik JR; Podolsky DK
    Nat Rev Drug Discov; 2006 Mar; 5(3):197-209. PubMed ID: 16518373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-6 signaling pathway in targeted therapy for cancer.
    Guo Y; Xu F; Lu T; Duan Z; Zhang Z
    Cancer Treat Rev; 2012 Nov; 38(7):904-10. PubMed ID: 22651903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-6 in Rheumatoid Arthritis.
    Pandolfi F; Franza L; Carusi V; Altamura S; Andriollo G; Nucera E
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammation, peptides and biological therapy.
    Atreya R; Neurath MF
    Dig Dis; 2009; 27 Suppl 1():42-7. PubMed ID: 20203496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity.
    Nace G; Evankovich J; Eid R; Tsung A
    J Innate Immun; 2012; 4(1):6-15. PubMed ID: 22086146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials.
    Gerner RR; Moschen AR; Tilg H
    Dig Dis; 2013; 31(3-4):328-35. PubMed ID: 24246983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic targets for rheumatoid arthritis: Progress and promises.
    Alghasham A; Rasheed Z
    Autoimmunity; 2014 Mar; 47(2):77-94. PubMed ID: 24437572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
    Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
    Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-6: regulator of Treg/Th17 balance.
    Kimura A; Kishimoto T
    Eur J Immunol; 2010 Jul; 40(7):1830-5. PubMed ID: 20583029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-23 promotes tumour incidence and growth.
    Langowski JL; Zhang X; Wu L; Mattson JD; Chen T; Smith K; Basham B; McClanahan T; Kastelein RA; Oft M
    Nature; 2006 Jul; 442(7101):461-5. PubMed ID: 16688182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene of the month: Interleukin 6 (IL-6).
    Ataie-Kachoie P; Pourgholami MH; Richardson DR; Morris DL
    J Clin Pathol; 2014 Nov; 67(11):932-7. PubMed ID: 25031389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
    Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
    Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies for chronic refractory asthma and pipeline developments.
    Polosa R; Casale T
    Drug Discov Today; 2012 Jun; 17(11-12):591-9. PubMed ID: 22306350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease.
    Abraham C; Cho JH
    Annu Rev Med; 2009; 60():97-110. PubMed ID: 18976050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.